XML 176 R2.htm IDEA: XBRL DOCUMENT
v3.23.1

Pay vs Performance Disclosure | 12 Months Ended
--- | ---
Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($)
Pay vs Performance Disclosure [Table] |  |  |
Pay vs Performance [Table Text Block] | Pay Versus Performance The Compensation Committee oversees our compensation programs that are designed to attract, retain, motivate, and align the interests of our named executive officers with that of stockholders. We link executive pay with shareholder interests through a blend of short- and long-term measures. In 2022, incentive pay made up 88 percent of our CEO’s target compensation and, on average, 79 percent of our other named executive officers’ target compensation. The high utilization of incentive compensation results in higher total realized pay when leadership exceeds their performance targets. Conversely, failure to achieve approved targets results in lower realized pay including the possibility that some awards pay zero at the end of their performance period. The compensation actually paid, as calculated under SEC rules (“CAP”), for the CEO and the average for non-CEO named executive officers and certain financial performance of the Company in each of the last three fiscal years is shown in the table below. The CAP does not reflect the actual amount of compensation earned or paid during the applicable year. ​ PAY VERSUS PERFORMANCE TABLE The following table sets forth information regarding the Company’s CAP and certain other Company financial information for fiscal years 2022, 2021 and 2020.
​ | Year | ​ | ​ | Summary Compensation Table Total for CEO | ​ | ​ | Compensation Actually Paid to CEO | ​ | ​ | Average Summary Compensation Total for Non- CEO NEO’s | ​ | ​ | Average Compensation Actually Paid to Non-CEO NEO’s | ​ | ​ | Value of Initial Fixed $100 Investment Based on: | ​ | ​ | Net Income ($ m’s)(3) | ​ | ​ | Adjusted EBITDA ($ m’s)(4) | ​
​ | Total Shareholder Return(2) | ​ | ​ | Peer Group Total Shareholder Return(1)(2) | ​
​ | (a) | ​ | ​ | (b) | ​ | ​ | (c) | ​ | ​ | (d) | ​ | ​ | (e) | ​ | ​ | (f) | ​ | ​ | (g) | ​ | ​ | (h) | ​ | ​ | (i) | ​
​ | 2022 | ​ | ​ | ​ | $ | 6,851,340 | ​ | ​ | ​ | ​ | $ | 887,122 | ​ | ​ | ​ | ​ | $ | 2,026,308 | ​ | ​ | ​ | ​ | $ | 910,108 | ​ | ​ | ​ | ​ | $ | 85 | ​ | ​ | ​ | ​ | $ | 90 | ​ | ​ | ​ | ​ | $ | 15.9 | ​ | ​ | ​ | ​ | $ | 212.7 | ​ | ​
​ | 2021 | ​ | ​ | ​ | $ | 6,942,484 | ​ | ​ | ​ | ​ | $ | 5,456,804 | ​ | ​ | ​ | ​ | $ | 2,057,810 | ​ | ​ | ​ | ​ | $ | 1,806,206 | ​ | ​ | ​ | ​ | $ | 133 | ​ | ​ | ​ | ​ | $ | 140 | ​ | ​ | ​ | ​ | $ | 42.0 | ​ | ​ | ​ | ​ | $ | 204.0 | ​ | ​
​ | 2020 | ​ | ​ | ​ | $ | 9,344,282 | ​ | ​ | ​ | ​ | $ | 13,553,554 | ​ | ​ | ​ | ​ | $ | 2,447,635 | ​ | ​ | ​ | ​ | $ | 3,526,611 | ​ | ​ | ​ | ​ | $ | 132 | ​ | ​ | ​ | ​ | $ | 126 | ​ | ​ | ​ | ​ | $ | 145.5 | ​ | ​ | ​ | ​ | $ | 112.6 | ​ | ​
​ (1) Represents the weighted peer group TSR, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated. The peer group used is the S&P Pharmaceuticals Select Index. ​ (2) The comparison of total shareholder returns assumes that $100 was invested on December 31, 2019 in Pacira and the S&P Pharmaceuticals Select Index, and that any dividends were reinvested when and as paid. ​ (3) Represents the amount of net income reflected in the Company’s audited financial statement for the applicable year. Included in net income in 2020 was a $126.6 million income tax benefit related to the release of a valuation allowance on deferred tax assets. ​ (4) The company selected measure is adjusted EBITDA, calculated and defined as described in the section on page 67 titled “2022 Cash LTIP Targets and Earned Awards”. ​ The CEO and named executive officers included in the above compensation columns are as follows:
​ | Year | ​ | ​ | CEO | ​ | ​ | Named Executive Officers Other Than the CEO | ​
​ | 2022 | ​ | ​ | David Stack | ​ | ​ | Charles A. Reinhart, III; Kristen Williams; Daryl Gaugler; Anthony Molloy | ​
​ | 2021 | ​ | ​ | David Stack | ​ | ​ | Charles A. Reinhart, III; Max Reinhardt; Roy Winston; Jonathan Slonin | ​
​ | 2020 | ​ | ​ | David Stack | ​ | ​ | Charles A. Reinhart, III; Kristen Williams; Max Reinhardt; Donald Manning | ​
The following table reconciles the amounts reported in the Summary Compensation Table (“SCT”) (column (b) above) to the CAP (column (c) above) to our CEO, David Stack, in the years presented:
​ | Item | ​ | ​ | 2020 | ​ | ​ | 2021 | ​ | ​ | 2022 | ​
​ | SCT Total | ​ | ​ | ​ | $ | 9,344,282 | ​ | ​ | ​ | ​ | $ | 6,942,484 | ​ | ​ | ​ | ​ | $ | 6,851,340 | ​ | ​
​ | Less: Stock and Option Award Values Reported in the SCT for the Covered Year | ​ | ​ | ​ | $ | (7,753,334) | ​ | ​ | ​ | ​ | $ | (4,786,294) | ​ | ​ | ​ | ​ | $ | (5,307,430) | ​ | ​
​ | Plus: Year-End Fair Value for Stock and Option Awards Granted in the Covered Year | ​ | ​ | ​ | $ | 9,920,391 | ​ | ​ | ​ | ​ | $ | 4,184,670 | ​ | ​ | ​ | ​ | $ | 3,140,460 | ​ | ​
​ | Change in Fair Value of Outstanding Unvested Stock and Option Awards from Prior Years | ​ | ​ | ​ | $ | 1,933,127 | ​ | ​ | ​ | ​ | $ | (449,125) | ​ | ​ | ​ | ​ | $ | (3,417,566) | ​ | ​
​ | Change in Fair Value of Stock and Option Awards that Vested in the Covered Year from Prior Years | ​ | ​ | ​ | $ | 109,088 | ​ | ​ | ​ | ​ | $ | (434,931) | ​ | ​ | ​ | ​ | $ | (379,682) | ​ | ​
​ | Plus: Fair Value as of Vesting Date of any Awards Granted and Vested in the Same Year | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​
​ | Less: Fair Value at Prior Year-End of Stock and Option Awards Forfeited During the Covered Year | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​
​ | Compensation Actually Paid | ​ | ​ | ​ | $ | 13,553,554 | ​ | ​ | ​ | ​ | $ | 5,456,804 | ​ | ​ | ​ | ​ | $ | 887,122 | ​ | ​
Stock and Option Award Valuations: Stock option grant date fair values are calculated based on the Black-Scholes option pricing model as of date of grant. Adjustments have been made using stock option fair values as of each measurement date using the stock price as of the measurement date and updated assumptions (i.e., term, volatility, dividend yield, risk free rate) as of the measurement date. Time-vested RSU grant date fair values are calculated using the stock price as of the date of grant. Adjustments have been made using the stock price as of year-end and as of each date of vest, as applicable. The following table reconciles the amounts reported in the SCT (column (d) above) to the average CAP (column (e) above) to our non-CEO named executive officers (as listed above) in the years presented:
​ | Item | ​ | ​ | 2020 | ​ | ​ | 2021 | ​ | ​ | 2022 | ​
​ | SCT Total | ​ | ​ | ​ | $ | 2,447,635 | ​ | ​ | ​ | ​ | $ | 2,057,810 | ​ | ​ | ​ | ​ | $ | 2,026,308 | ​ | ​
​ | Less: Stock and Option Award Values Reported in the SCT for the Covered Year | ​ | ​ | ​ | $ | (1,734,857) | ​ | ​ | ​ | ​ | $ | (1,120,926) | ​ | ​ | ​ | ​ | $ | (1,291,208) | ​ | ​
​ | Plus: Year-End Fair Value for Stock and Option Awards Granted in the Covered Year | ​ | ​ | ​ | $ | 2,302,390 | ​ | ​ | ​ | ​ | $ | 1,029,489 | ​ | ​ | ​ | ​ | $ | 731,726 | ​ | ​
​ | Change in Fair Value of Outstanding Unvested Stock and Option Awards from Prior Years | ​ | ​ | ​ | $ | 471,414 | ​ | ​ | ​ | ​ | $ | (101,546) | ​ | ​ | ​ | ​ | $ | (533,189) | ​ | ​
​ | Change in Fair Value of Stock and Option Awards that Vested in the Covered Year from Prior Years | ​ | ​ | ​ | $ | 40,029 | ​ | ​ | ​ | ​ | $ | (58,622) | ​ | ​ | ​ | ​ | $ | (23,529) | ​ | ​
​ | Plus: Fair Value as of Vesting Date of any Awards Granted and Vested in the Same Year | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​
​ | Less: Fair Value at Prior Year-End of Stock and Option Awards Forfeited During the Covered Year | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​
​ | Compensation Actually Paid | ​ | ​ | ​ | $ | 3,526,611 | ​ | ​ | ​ | ​ | $ | 1,806,206 | ​ | ​ | ​ | ​ | $ | 910,108 | ​ | ​
Stock and Option Award Valuations: Stock option grant date fair values are calculated based on the Black-Scholes option pricing model as of date of grant. Adjustments have been made using stock option fair values as of each measurement date using the stock price as of the measurement date and updated assumptions (i.e., term, volatility, dividend yield, risk free rate) as of the measurement date. Time-vested RSU grant date fair values are calculated using the stock price as of the date of grant. Adjustments have been made using the stock price as of year-end and as of each date of vest, as applicable. |  |
Company Selected Measure Name | Adjusted EBITDA |  |
Named Executive Officers, Footnote [Text Block] | The CEO and named executive officers included in the above compensation columns are as follows:
​ | Year | ​ | ​ | CEO | ​ | ​ | Named Executive Officers Other Than the CEO | ​
​ | 2022 | ​ | ​ | David Stack | ​ | ​ | Charles A. Reinhart, III; Kristen Williams; Daryl Gaugler; Anthony Molloy | ​
​ | 2021 | ​ | ​ | David Stack | ​ | ​ | Charles A. Reinhart, III; Max Reinhardt; Roy Winston; Jonathan Slonin | ​
​ | 2020 | ​ | ​ | David Stack | ​ | ​ | Charles A. Reinhart, III; Kristen Williams; Max Reinhardt; Donald Manning | ​
Peer Group Issuers, Footnote [Text Block] | (1) Represents the weighted peer group TSR, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated. The peer group used is the S&P Pharmaceuticals Select Index. ​ (2) The comparison of total shareholder returns assumes that $100 was invested on December 31, 2019 in Pacira and the S&P Pharmaceuticals Select Index, and that any dividends were reinvested when and as paid. |  |
PEO Total Compensation Amount | $ 6,851,340 | $ 6,942,484 | $ 9,344,282
PEO Actually Paid Compensation Amount | $ 887,122 | 5,456,804 | 13,553,554
Adjustment To PEO Compensation, Footnote [Text Block] | The following table reconciles the amounts reported in the Summary Compensation Table (“SCT”) (column (b) above) to the CAP (column (c) above) to our CEO, David Stack, in the years presented:
​ | Item | ​ | ​ | 2020 | ​ | ​ | 2021 | ​ | ​ | 2022 | ​
​ | SCT Total | ​ | ​ | ​ | $ | 9,344,282 | ​ | ​ | ​ | ​ | $ | 6,942,484 | ​ | ​ | ​ | ​ | $ | 6,851,340 | ​ | ​
​ | Less: Stock and Option Award Values Reported in the SCT for the Covered Year | ​ | ​ | ​ | $ | (7,753,334) | ​ | ​ | ​ | ​ | $ | (4,786,294) | ​ | ​ | ​ | ​ | $ | (5,307,430) | ​ | ​
​ | Plus: Year-End Fair Value for Stock and Option Awards Granted in the Covered Year | ​ | ​ | ​ | $ | 9,920,391 | ​ | ​ | ​ | ​ | $ | 4,184,670 | ​ | ​ | ​ | ​ | $ | 3,140,460 | ​ | ​
​ | Change in Fair Value of Outstanding Unvested Stock and Option Awards from Prior Years | ​ | ​ | ​ | $ | 1,933,127 | ​ | ​ | ​ | ​ | $ | (449,125) | ​ | ​ | ​ | ​ | $ | (3,417,566) | ​ | ​
​ | Change in Fair Value of Stock and Option Awards that Vested in the Covered Year from Prior Years | ​ | ​ | ​ | $ | 109,088 | ​ | ​ | ​ | ​ | $ | (434,931) | ​ | ​ | ​ | ​ | $ | (379,682) | ​ | ​
​ | Plus: Fair Value as of Vesting Date of any Awards Granted and Vested in the Same Year | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​
​ | Less: Fair Value at Prior Year-End of Stock and Option Awards Forfeited During the Covered Year | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​
​ | Compensation Actually Paid | ​ | ​ | ​ | $ | 13,553,554 | ​ | ​ | ​ | ​ | $ | 5,456,804 | ​ | ​ | ​ | ​ | $ | 887,122 | ​ | ​
Stock and Option Award Valuations: Stock option grant date fair values are calculated based on the Black-Scholes option pricing model as of date of grant. Adjustments have been made using stock option fair values as of each measurement date using the stock price as of the measurement date and updated assumptions (i.e., term, volatility, dividend yield, risk free rate) as of the measurement date. Time-vested RSU grant date fair values are calculated using the stock price as of the date of grant. Adjustments have been made using the stock price as of year-end and as of each date of vest, as applicable. |  |
Non-PEO NEO Average Total Compensation Amount | $ 2,026,308 | 2,057,810 | 2,447,635
Non-PEO NEO Average Compensation Actually Paid Amount | $ 910,108 | 1,806,206 | 3,526,611
Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | The following table reconciles the amounts reported in the SCT (column (d) above) to the average CAP (column (e) above) to our non-CEO named executive officers (as listed above) in the years presented:
​ | Item | ​ | ​ | 2020 | ​ | ​ | 2021 | ​ | ​ | 2022 | ​
​ | SCT Total | ​ | ​ | ​ | $ | 2,447,635 | ​ | ​ | ​ | ​ | $ | 2,057,810 | ​ | ​ | ​ | ​ | $ | 2,026,308 | ​ | ​
​ | Less: Stock and Option Award Values Reported in the SCT for the Covered Year | ​ | ​ | ​ | $ | (1,734,857) | ​ | ​ | ​ | ​ | $ | (1,120,926) | ​ | ​ | ​ | ​ | $ | (1,291,208) | ​ | ​
​ | Plus: Year-End Fair Value for Stock and Option Awards Granted in the Covered Year | ​ | ​ | ​ | $ | 2,302,390 | ​ | ​ | ​ | ​ | $ | 1,029,489 | ​ | ​ | ​ | ​ | $ | 731,726 | ​ | ​
​ | Change in Fair Value of Outstanding Unvested Stock and Option Awards from Prior Years | ​ | ​ | ​ | $ | 471,414 | ​ | ​ | ​ | ​ | $ | (101,546) | ​ | ​ | ​ | ​ | $ | (533,189) | ​ | ​
​ | Change in Fair Value of Stock and Option Awards that Vested in the Covered Year from Prior Years | ​ | ​ | ​ | $ | 40,029 | ​ | ​ | ​ | ​ | $ | (58,622) | ​ | ​ | ​ | ​ | $ | (23,529) | ​ | ​
​ | Plus: Fair Value as of Vesting Date of any Awards Granted and Vested in the Same Year | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​
​ | Less: Fair Value at Prior Year-End of Stock and Option Awards Forfeited During the Covered Year | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | — | ​ | ​
​ | Compensation Actually Paid | ​ | ​ | ​ | $ | 3,526,611 | ​ | ​ | ​ | ​ | $ | 1,806,206 | ​ | ​ | ​ | ​ | $ | 910,108 | ​ | ​
Stock and Option Award Valuations: Stock option grant date fair values are calculated based on the Black-Scholes option pricing model as of date of grant. Adjustments have been made using stock option fair values as of each measurement date using the stock price as of the measurement date and updated assumptions (i.e., term, volatility, dividend yield, risk free rate) as of the measurement date. Time-vested RSU grant date fair values are calculated using the stock price as of the date of grant. Adjustments have been made using the stock price as of year-end and as of each date of vest, as applicable |  |
Compensation Actually Paid vs. Total Shareholder Return [Text Block] | Pay versus Performance: Total Shareholder Return The chart below compares the CAP to our CEO and the average CAP to our non-CEO named executive officers with the TSR of the Company and its selected peer group—the S&P Pharmaceuticals Select Index. As described on page 68, this index is the same one used in our cash LTIP plan. |  |
Compensation Actually Paid vs. Net Income [Text Block] | Pay versus Performance: Net Income The chart below compares the CAP to our CEO and the average CAP to our non-CEO named executive officers with the Company’s net income. Included in net income in 2020 was a $126.6 million income tax benefit related to the release of a valuation allowance on deferred tax assets. |  |
Compensation Actually Paid vs. Company Selected Measure [Text Block] | Pay versus Performance: Adjusted EBITDA (Non-GAAP) The chart below compares the CAP to our CEO and the average CAP to our non-CEO named executive officers with the Company’s adjusted EBITDA, which includes GAAP to non-GAAP adjustments that reflect how the Company’s management analyzes its financial results. The adjusted EBITDA figures presented here are unlikely to be comparable with adjusted EBITDA disclosures released by other companies. |  |
Tabular List [Table Text Block] | Tabular List of Financial and Non-Financial Performance Measures Used to Link Compensation Actually Paid to Named Executive Officers for the Year Ended December 31, 2022 to Company Performance
​ | Most Important Financial Measures | ​ | ​ | ​ | Most Important Non-Financial Measures | ​
​ | Adjusted EBITDA | ​ | ​ | ​ | Clinical Development | ​
​ | Total Net Revenues | ​ | ​ | ​ | Pipeline Development Milestones | ​
​ | Adjusted Earnings Per Share | ​ | ​ | ​ | Commercial Manufacturing Goals | ​
​ | ​ | ​ | ​ | ​ | Pipeline Development Milestones | ​
Total Shareholder Return Amount | $ 85 | 133 | 132
Peer Group Total Shareholder Return Amount | 90 | 140 | 126
Net Income (Loss) | $ 15,900,000 | $ 42,000,000 | $ 145,500,000
Company Selected Measure Amount | 212,700,000 | 204,000,000 | 112,600,000
PEO Name | David Stack |  |
Incentive Pay As A Percentage Of CEOs Target Compensation | 88.00% |  |
Incentive Pay as a Percentage of Other Named Executive Officers Target Compensation | 79.00% |  |
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount |  |  | $ 126,600,000
Measure [Axis]: 1 |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Measure Name | Adjusted EBITDA |  |
Non-GAAP Measure Description [Text Block] | (4) The company selected measure is adjusted EBITDA, calculated and defined as described in the section on page 67 titled “2022 Cash LTIP Targets and Earned Awards”. |  |
Measure [Axis]: 2 |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Measure Name | Total Net Revenues |  |
Measure [Axis]: 3 |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Measure Name | Adjusted Earnings Per Share |  |
David Stack [Member] | Less: Stock and Option Award Values Reported in the SCT for the Covered Year |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | $ (5,307,430) | $ (4,786,294) | (7,753,334)
David Stack [Member] | Plus: Year-End Fair Value for Stock and Option Awards Granted in the Covered Year |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | 3,140,460 | 4,184,670 | 9,920,391
David Stack [Member] | Change in Fair Value of Outstanding Unvested Stock and Option Awards from Prior Years |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | (3,417,566) | (449,125) | 1,933,127
David Stack [Member] | Change in Fair Value of Stock and Option Awards that Vested in the Covered Year from Prior Years |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | (379,682) | (434,931) | 109,088
Non-PEO NEO [Member] | Less: Stock and Option Award Values Reported in the SCT for the Covered Year |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | (1,291,208) | (1,120,926) | (1,734,857)
Non-PEO NEO [Member] | Plus: Year-End Fair Value for Stock and Option Awards Granted in the Covered Year |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | 731,726 | 1,029,489 | 2,302,390
Non-PEO NEO [Member] | Change in Fair Value of Outstanding Unvested Stock and Option Awards from Prior Years |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | (533,189) | (101,546) | 471,414
Non-PEO NEO [Member] | Change in Fair Value of Stock and Option Awards that Vested in the Covered Year from Prior Years |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | $ (23,529) | $ (58,622) | $ 40,029

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_NonGaapMeasureDescriptionTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | pcrx_IncentivePayAsAPercentageOfCEOsTargetCompensation
Namespace Prefix: | pcrx_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | pcrx_IncentivePayAsAPercentageOfOtherNamedExecutiveOfficersTargetCompensation
Namespace Prefix: | pcrx_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7 Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2 + Details
Name: | us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=3
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=pcrx_DavidStackMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=pcrx_EquityAwardsValueInCompensationTableForTheApplicableYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=pcrx_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=pcrx_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=pcrx_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |